Clinical efficacy of daratumumab

Clinical efficacy of daratumumab monotherapy in patients with ...

The most common (≥20%) TEAEs included fatigue, nausea, anemia, back pain, cough, upper respiratory tract infection, thrombocytopenia, and neutropenia.

Clinical efficacy of daratumumab monotherapy in patients with ...

A pooled analysis of 2 daratumumab trials showed no new safety signals, an overall response rate of 31%, and deep and durable responses.

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI

A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug daratumumab (Darzalex) to a standard ...

Efficacy and safety of daratumumab in the treatment of relapsed ...

Despite the promising results of daratumumab in clinical trials, its application for patients with RRMM has been limited. There is a need ...

Clinical efficacy of daratumumab (DARA)-based second line therapy ...

Our findings suggest that DARA-exposed MM pts may derive benefit from DARA retreatment in subsequent lines of therapy similarly to pts who were DARA-naïve ...

Daratumumab-Based Therapeutic Approaches and Clinical ...

This retrospective review analyzed 112 patients who received daratumumab between 2012 and 2020. Tolerability, and efficacy based on prior lines (PL) of therapy ...

Clinical efficacy of daratumumab, pomalidomide, and ...

This article presents a retrospective analysis of the safety and efficacy of DARA in combination with pomalidomide (POM) and dexamethasone.

Efficacy of Daratumumab-Containing Regimens Among Patients ...

Daratumumab-containing therapies are effective regimens in patients progressing on lenalidomide maintenance.

Addition of daratumumab to multiple myeloma backbone regimens ...

Daratumumab has shown clinical benefit in multiple myeloma. We aimed to evaluate the safety and efficacy of adding daratumumab to backbone ...

Efficacy of daratumumab monotherapy in real-world heavily ...

Daratumumab is a promising new agent for relapsed/refractory multiple myeloma (RRMM). However, there are limited data on its clinical activity and ...

The clinical efficacy of a daratumumab-based regimen in relapsed ...

The daratumumab-based salvage regimen offers patients with R/R-AL the opportunity of remission with acceptable tolerability, creating the possibility of ...

Efficacy of Daratumumab Based Regimens Compared to Standard ...

Daratumumab (Dara) is a human anti-CD38 monoclonal antibody approved for multiple myeloma (MM) treatment. Dara has shown promising efficacy and ...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for ...

The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with ...

Clinical Trials Using Daratumumab - NCI

The clinical trials on this list are studying daratumumab. All trials on the list are NCI-supported clinical trials, which are sponsored or otherwise ...

a phase 1, dose-escalation study (MMY1003) - SpringerLink

Daratumumab monotherapy demonstrated favorable safety and efficacy in relapsed/refractory multiple myeloma (RRMM) patients in the global phase 1/2 GEN501 and ...

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab ...

The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease ... Daratumumab is a monoclonal ...

Safety and efficacy of daratumumab with lenalidomide and ...

Encouraging early activity is seen with marked reduction in M-protein and 8/11 patients (72%) achieving PR or better. Part 2 data will be presented. Clinical ...

Paper: Clinical Efficacy of Daratumumab Monotherapy in Patients ...

29 Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma Clinically Relevant ...

DARZALEX® (daratumumab)-based maintenance regimens show ...

The efficacy of DARZALEX FASPRO® in combination with lenalidomide for maintenance has not been established. The primary endpoint is PFS, and ...

Clinical efficacy of retreatment of daratumumab‐based therapy (D2 ...

This study aimed to analyze the clinical efficacy of daratumumab-based retreatment (D2) in patients who are daratumumab refractory MM.